Long-term observation of children with primary immune thrombocytopenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the clinical characteristics, treatment methods, and prognosis of pediatric patients diagnosed with primary immune thrombocytopenia (ITP) in China. It will collect data from medical records and utilize questionnaires to assess patient exposure, with a focus on long-term follow-up to gather prognostic information. The study seeks to establish a comprehensive understanding of ITP in children, addressing the current gaps in large-scale prospective cohort studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 6-17 years old (including both ends), male and female;
* Diagnosis of ITP.

Exclusion Criteria:

* Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
* The expected follow-up period is less than 3 months.

Where it's running

• Chinese Academy of Medical Science and Blood Disease Hospital
  Tianjin, China Recruiting

Study contacts

• Principal investigator: Lei Zhang, MD — Chinese Academy of Medical Science and Blood Disease Hospital
• Study coordinator: Ting Sun, MD
• Email: sunting@ihcams.ac.cn
• Phone: 02223909009

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• What patients with primary ITP prefer in their treatment

  This survey-based study in the US will ask adults with primary ITP about which treatment options they prefer and why.

  Recruiting Novartis · East Hanover, New Jersey · NCT07786077

• SG301 SC Injection safety in adults with primary ITP

  This Phase 2 study tests SG301 SC injection at two doses versus placebo in adults with primary immune thrombocytopenia to see if it is safe and helps raise platelet counts.

  Recruiting at 14 sites Phase 2 Hangzhou Sumgen Biotech Co., Ltd. · Fuzhou, Fujian and 21 other locations · NCT07710248

• Romiplostim plus prednisone vs prednisone alone in adults with newly diagnosed ITP

  This phase 3 trial tests whether adding romiplostim to prednisone helps adults with newly diagnosed primary ITP respond better than prednisone alone.

  Recruiting at 3 sites Phase 3 Amgen · Long Beach, California and 2 other locations · NCT07700238

• TQB3473 tablets for treating adult primary immune thrombocytopenia

  This study is testing if TQB3473 tablets can help adults with chronic immune thrombocytopenia who haven't responded well to standard treatments feel better and have more stable blood platelet levels.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 52 other locations · NCT06900920

• Using Eltrombopag as a first treatment for Primary Immune Thrombocytopenia

  This study is testing if a new medication called eltrombopag can help people who are newly diagnosed with Primary Immune Thrombocytopenia by increasing their platelet counts and reducing bleeding.

  Recruiting Phase 1/2 Renata PLC · Dhaka · NCT06531018

• High-dose dexamethasone plus orelabrutinib versus placebo for newly diagnosed adult ITP

  This trial tests whether adding orelabrutinib to high-dose dexamethasone helps adults newly diagnosed with primary ITP raise and maintain their platelet counts compared with placebo.

  Recruiting Phase 3 Shandong University · Jinan, Shandong · NCT07559331

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.